Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Trials

Rachel Phillips¹  Victoria Cornelius¹  Melanie Almonte²  Dragana Milojkovic²  Taryn Youngstein²  Mark Thursz²  Asad Charania²  Onn Min Kon²  Lucy Cook²  Tina Shturova²  Graham Cooke²  Nikhil Vergis²  Clio Pilay²  Andew J. Innes²  Alexia Katsarou²  Richard Turner²  Nichola Cooper²  Michelle Willicombe²  Svetlana Cherlin³  James Wason³ 

[1] Imperial Clinical Trials Unit and Imperial College, London, UK;Imperial College, London and Imperial NHS Trust, London, UK;Newcastle Clinical Trials Unit and Newcastle University, Newcastle upon Tyne, UK;

关键词: COVID-19;    coronavirus;    randomised controlled trial;    protocol;    pneumonia;    fostamatinib;    ruxolitinib;   

DOI  :  10.1186/s13063-021-05190-z

来源: Springer

【 授权许可】

CC BY